Now in its 9th year, Current Clinical Pharmacology continues to strive for excellence by providing expert critical appraisals of topical issues in the discipline of Clinical Pharmacology as well as disseminating results of drug trials in humans. While indexed in mainstream databases, e.g. Chemical Abstracts, EMBASE, MEDLINE/PubMed, PubMed Central and Scopus, the journal is also expecting its first Thomson Reuters Impact Factor in a not too distant future. This is very good news indeed, however substantial work still needs to be done to best serve our readership. This editorial highlights the current and future directions of the journal as well as some strategies to further enhance its visibility within the scientific community.